CA2515481A1 - An expression cassette and vector for transient or stable expression of exogenous molecules - Google Patents

An expression cassette and vector for transient or stable expression of exogenous molecules Download PDF

Info

Publication number
CA2515481A1
CA2515481A1 CA002515481A CA2515481A CA2515481A1 CA 2515481 A1 CA2515481 A1 CA 2515481A1 CA 002515481 A CA002515481 A CA 002515481A CA 2515481 A CA2515481 A CA 2515481A CA 2515481 A1 CA2515481 A1 CA 2515481A1
Authority
CA
Canada
Prior art keywords
expression cassette
sequence
vector
seq
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002515481A
Other languages
English (en)
French (fr)
Inventor
William P. Sisk
Holly Prentice
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen MA Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2515481A1 publication Critical patent/CA2515481A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Sampling And Sample Adjustment (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Tents Or Canopies (AREA)
  • Paints Or Removers (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
CA002515481A 2003-02-14 2004-02-13 An expression cassette and vector for transient or stable expression of exogenous molecules Abandoned CA2515481A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US44817903P 2003-02-14 2003-02-14
US60/448,179 2003-02-14
PCT/US2004/004407 WO2004074439A2 (en) 2003-02-14 2004-02-13 An expression cassette and vector for transient or stable expression of exogenous molecules

Publications (1)

Publication Number Publication Date
CA2515481A1 true CA2515481A1 (en) 2004-09-02

Family

ID=32908549

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002515481A Abandoned CA2515481A1 (en) 2003-02-14 2004-02-13 An expression cassette and vector for transient or stable expression of exogenous molecules

Country Status (21)

Country Link
US (2) US7494805B2 (cg-RX-API-DMAC7.html)
EP (1) EP1594955B1 (cg-RX-API-DMAC7.html)
JP (2) JP2006517802A (cg-RX-API-DMAC7.html)
KR (1) KR20050101554A (cg-RX-API-DMAC7.html)
CN (1) CN1774500B (cg-RX-API-DMAC7.html)
AT (1) ATE553185T1 (cg-RX-API-DMAC7.html)
AU (1) AU2004213797B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0407487A (cg-RX-API-DMAC7.html)
CA (1) CA2515481A1 (cg-RX-API-DMAC7.html)
DK (1) DK1594955T3 (cg-RX-API-DMAC7.html)
EA (2) EA008439B1 (cg-RX-API-DMAC7.html)
ES (1) ES2384973T3 (cg-RX-API-DMAC7.html)
IL (1) IL170178A (cg-RX-API-DMAC7.html)
IS (1) IS7974A (cg-RX-API-DMAC7.html)
MX (1) MXPA05008523A (cg-RX-API-DMAC7.html)
NO (1) NO20054202L (cg-RX-API-DMAC7.html)
NZ (1) NZ542316A (cg-RX-API-DMAC7.html)
PL (1) PL378110A1 (cg-RX-API-DMAC7.html)
RS (1) RS20050614A (cg-RX-API-DMAC7.html)
WO (1) WO2004074439A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200506413B (cg-RX-API-DMAC7.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL378110A1 (pl) 2003-02-14 2006-03-06 Biogen Idec Ma Inc. Kaseta ekspresyjna i wektor do przejściowej albo stabilnej ekspresji egzogennych cząsteczek
UA87467C2 (xx) 2003-09-19 2009-07-27 Янссен Фармацевтика Н.В 4-((феноксіалкіл)тіо)феноксіоцтова кислота та її аналоги$4-((феноксиалкил)тио)феноксиуксусная кислота и ее аналоги
BRPI0415446A (pt) * 2003-10-14 2006-12-05 Biogen Idec Inc recombinação mediada por flp
EP1733034A4 (en) * 2004-03-15 2010-01-20 Biogen Idec Inc METHOD AND CONSTRUCTS FOR THE EXPRESSION OF POLYPEPTIDE MULTIMERS IN EUKARYONTIC CELLS USING ALTERNATIVE SPLEISSEN
MY147518A (en) 2004-09-15 2012-12-31 Janssen Pharmaceutica Nv 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
JO3006B1 (ar) 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
GB0606190D0 (en) 2006-03-28 2006-05-10 Isis Innovation Construct
PE20080188A1 (es) 2006-04-18 2008-03-10 Janssen Pharmaceutica Nv Derivados del acido benzoazepin-oxi-acetico como agonistas de ppar-delta usados para aumentar hdl-c, reducir ldl-c y reducir colesterol
CN101535338A (zh) * 2006-10-18 2009-09-16 斯克利普斯研究院 在哺乳动物细胞中将非天然氨基酸遗传掺入蛋白质
WO2011017319A1 (en) 2009-08-03 2011-02-10 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Methods of treating disorders associated with protein polymerization
US9072772B2 (en) 2009-11-05 2015-07-07 University of Pittsburgh—of the Commonwealth System of Higher Education Methods of treating disorders associated with protein aggregation
US8809617B2 (en) * 2009-11-05 2014-08-19 The University of Pittsburgh—Of the Commonwealth System of Higher Education Automated high-content live animal drug screening using C. elegans
MX2012006884A (es) * 2009-12-21 2012-07-04 Sanofi Sa Anmal transgenico no humano y sus usos.
UY33126A (es) * 2009-12-21 2011-07-29 Sanofi Sa Animal transgénico no humano y sus usos
US8993316B2 (en) 2011-11-16 2015-03-31 Brian P. Hanley Methods and compositions for gene therapy and GHRH therapy
WO2013158664A2 (en) 2012-04-17 2013-10-24 Kythera Biopharmaceuticals, Inc. Use of engineered viruses to specifically kill senescent cells
US9816102B2 (en) 2012-09-13 2017-11-14 Indiana University Research And Technology Corporation Compositions and systems for conferring disease resistance in plants and methods of use thereof
BR122020023058B1 (pt) 2012-12-10 2023-12-05 Biogen Ma Inc Ácido nucleico isolado ou ácidos nucleicos
MX2015013842A (es) * 2013-03-30 2017-01-23 Usha Biotech Ltd Metodos y constructos para expresar proteinas biologicamente activas en celulas de mamifero.
WO2015162930A1 (ja) * 2014-04-24 2015-10-29 一般社団法人 医療産業イノベーション機構 タンパク質発現を向上させる方法およびタンパク質発現用組成物
TWI747098B (zh) 2018-12-21 2021-11-21 美商美國禮來大藥廠 抗angptl3/8複合物抗體及其使用方法
US11415263B2 (en) * 2020-03-20 2022-08-16 Edwards Vacuum Llc Conversion kit for a support frame, a support frame and an integrated vacuum system mounted in a support frame

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
DK0897983T3 (da) 1991-10-25 2003-08-11 Immunex Corp Antistoffer mod CD40-L
ES2187505T3 (es) 1992-04-02 2003-06-16 Sembiosys Genetics Inc Elementos cis de proteinas de cuerpo oleoso como señales reguladoras.
AU698739B2 (en) 1995-06-06 1998-11-05 Isis Pharmaceuticals, Inc. Oligonucleotides having phosphorothioate linkages of high chiral purity
NZ311335A (en) 1995-06-07 1998-05-27 Immunex Corp Cd40l muteins and their use as ligands
US5985662A (en) 1995-07-13 1999-11-16 Isis Pharmaceuticals Inc. Antisense inhibition of hepatitis B virus replication
US6087129A (en) * 1996-01-19 2000-07-11 Betagene, Inc. Recombinant expression of proteins from secretory cell lines
US6448389B1 (en) * 1996-04-23 2002-09-10 The Wistar Institute Of Anatomy And Biology Human cytomegalovirus DNA constructs and uses therefor
CA2297375A1 (en) * 1997-07-24 1999-02-04 Valentis, Inc. Ghrh expression system and methods of use
EP1047774A1 (en) * 1998-01-16 2000-11-02 California Pacific Medical Center Research Institute Methods and compositions for gene delivery
US6455677B1 (en) * 1998-04-30 2002-09-24 Boehringer Ingelheim International Gmbh FAPα-specific antibody with improved producibility
EP0953639A1 (en) * 1998-04-30 1999-11-03 Boehringer Ingelheim International GmbH FAPalpha-specific antibody with improved producibility
CA2329259C (en) * 1998-05-27 2003-08-05 Avigen, Inc. Convection-enhanced delivery of aav vectors
EP1092768A1 (en) * 1999-10-16 2001-04-18 ARTEMIS Pharmaceuticals GmbH Conditional gene trapping construct for the disruption of genes
WO2001094599A1 (en) 2000-06-07 2001-12-13 Smittskyddsinstitutet Gene expression cassette and its use
AU7061401A (en) 2000-07-05 2002-01-14 Transgene Sa Chimeric promoters for controlling expression in smooth muscle cells
JP2002233374A (ja) * 2001-02-06 2002-08-20 Japan Science & Technology Corp 遺伝子導入及び/又は遺伝子欠損非ヒト動物作製用ベクター
DE10133407A1 (de) 2001-07-13 2003-01-23 Basf Ag Expressionskassetten zur transgenen Expression von Nukleinsäuren
US20030235823A1 (en) * 2002-06-24 2003-12-25 The University Of Alabama Nucleotide sequences that code for torsin genes, torsin proteins, and methods of using the same to treat protein-aggregation
PL378110A1 (pl) * 2003-02-14 2006-03-06 Biogen Idec Ma Inc. Kaseta ekspresyjna i wektor do przejściowej albo stabilnej ekspresji egzogennych cząsteczek

Also Published As

Publication number Publication date
EA200501296A1 (ru) 2006-04-28
NZ542316A (en) 2006-04-28
IL170178A (en) 2011-12-29
JP2010213718A (ja) 2010-09-30
NO20054202L (no) 2005-11-11
NO20054202D0 (no) 2005-09-09
AU2004213797A1 (en) 2004-09-02
US20060141625A1 (en) 2006-06-29
EA008439B1 (ru) 2007-06-29
EP1594955A2 (en) 2005-11-16
AU2004213797B2 (en) 2009-09-17
RS20050614A (sr) 2007-12-31
CN1774500B (zh) 2011-03-02
BRPI0407487A (pt) 2006-02-14
EP1594955A4 (en) 2006-07-19
WO2004074439A2 (en) 2004-09-02
PL378110A1 (pl) 2006-03-06
MXPA05008523A (es) 2005-10-20
WO2004074439A9 (en) 2004-12-23
US7494805B2 (en) 2009-02-24
HK1084690A1 (en) 2006-08-04
IS7974A (is) 2005-08-11
ATE553185T1 (de) 2012-04-15
DK1594955T3 (da) 2012-06-25
US20100158879A1 (en) 2010-06-24
EA200700469A1 (ru) 2008-10-30
WO2004074439A3 (en) 2004-10-28
KR20050101554A (ko) 2005-10-24
JP2006517802A (ja) 2006-08-03
ES2384973T3 (es) 2012-07-16
CN1774500A (zh) 2006-05-17
ZA200506413B (en) 2006-04-26
EP1594955B1 (en) 2012-04-11

Similar Documents

Publication Publication Date Title
US20100158879A1 (en) Expression cassette and vector for transient or stable expression of exogenous molecules
US20260132408A1 (en) Compositions and methods for transgene expression from an albumin locus
US20250255940A1 (en) Compositions and methods for expressing factor ix
JP7593920B2 (ja) 核酸構築物及び使用方法
JP2006517802A5 (cg-RX-API-DMAC7.html)
US6924365B1 (en) Optimized messenger RNA
EP0699240B1 (en) Gibbon ape leukemia virus-based retroviral vectors
EP0724639B1 (en) Methods for selection of recombinant host cells expressing high levels of a desired protein
KR20170132784A (ko) 글로빈 유전자 클러스터의 조절 요소를 포함하는 진핵생물 발현 벡터
CA1310601C (en) Expression vectors
HK1084690B (en) An expression cassette and vector for transient or stable expression of exogenous molecules
US20070134795A1 (en) Flp-mediated recombination
US20260115321A1 (en) Supplementation of liver enzyme expression
EA052702B1 (ru) Композиции и способы для экспрессии трансгена из локуса альбумина
HK40061317A (en) Compositions and methods for transgene expression from an albumin locus
EA052810B1 (ru) Конструкции нуклеиновых кислот и способы их применения
HK40051560A (en) Nucleic acid constructs and methods of use

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued